Less than a year after joining Nasdaq through a merger, Assembly Biosciences Inc. is tapping keen interest in the science behind its potentially curative preclinical hepatitis B virus (HBV) and Clostridium difficile-associated diarrhea (CDAD) programs through a $75 million public offering that will carry it well into 2017 or beyond.